Fulcrum Therapeutics dips after unveiling $150 million share sale

Shares of drug developer Fulcrum Therapeutics FULC.O fall 1.8% to $12.75 in extended trading

FULC kicks off public offering of $150 million worth of shares

Stock closed 46% higher on Monday after FULC unveiled trial data of blood disorder drug

J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering

Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes

7 of 9 brokerages rate the stock "buy" or higher, one "hold" and one "sell"; median PT $20 - data compiled by LSEG

As of last close, FULC up 176.4% YTD